Author Archives: Margarida Maia PhD

Most adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis who achieved low or no disease activity after four months on the recently approved Bimzelx (bimekizumab-bkzx) maintained their clinical response over at least two years. Two-year data from the Phase 3 clinical trials BE MOBILE 1 (NCT03928704)…

Certain gut bacteria may influence disease risk in ankylosing spondylitis (AS), with some bacteria associated with a protective effect against its development and others with a causal effect. These are the findings of a new study from China that analyzed genetic variants linked to different groups of gut bacteria…

Inflammation in people with axial spondyloarthritis (axSpA), which includes ankylosing spondylitis, is linked to multiple risk factors for cardiovascular disease, with differences evident between men and women, a Spanish study found. Cardiovascular disease refers to a group of conditions affecting the heart and blood vessels, ranging from arrhythmias and…

Rinvoq (upadacitinib) appears to be the most effective treatment to reduce disease activity in people with ankylosing spondylitis (AS), whether they had never been on tumor necrosis factor inhibitors (TNFi) or didn’t respond well to them, a study suggests. Because the observations come from indirect comparisons of data…

Both nonsteroidal anti-inflammatory drugs (NSAIDs) and more advanced medications appear to keep disease activity and structural damage under control in people with axial spondyloarthritis, including ankylosing spondylitis (AS), a real-world study found. The study, “Clinical and structural damage outcomes in axial spondyloarthritis patients receiving NSAIDs or advanced therapies:…

Tumor necrosis factor inhibitors (TNFi) appear to work as well and be as safe for adults with late-onset ankylosing spondylitis (AS) as they are for those with earlier symptoms, offering an additional treatment option for older patients, a real-world study suggests. The study, “Assessing safety and efficacy of…

Tapering off a TNF inhibitor — part of a class of medications that block pro-inflammatory molecules — may raise the risk of disease flare in people with spondyloarthritis, including among those with ankylosing spondylitis (AS), compared with staying on a standard dose, according to a review study. Further research…

Sarcopenia, a gradual loss of muscle mass and strength, may happen at a rather young age in people with ankylosing spondylitis (AS), a systematic review study has found, with researchers suggesting AS patients should take action early to build muscle tissue and age healthier. While no specific age range…

Nearly half of patients admitted to the hospital for ankylosing spondylitis (AS) are discharged to somewhere other than home or return to the hospital within three months, according to a study from over 150 hospitals under HCA Healthcare. Receiving medications such as opioids and steroids during a hospital stay…

While some people with recent-onset axial spondyloarthritis whose joint damage isn’t visible on an X-ray will progress within 10 years to ankylosing spondylitis (AS), where joint damage becomes evident on an X-ray, the risk is relatively low, a French study found. The risk was about halved in patients on TNF inhibitors, but more…